Literature DB >> 16480739

Vardenafil: a novel type 5 phosphodiesterase inhibitor reduces myocardial infarct size following ischemia/reperfusion injury via opening of mitochondrial K(ATP) channels in rabbits.

Fadi N Salloum1, Ramzi A Ockaili, Michael Wittkamp, Vijay R Marwaha, Rakesh C Kukreja.   

Abstract

cGMP and opening of mitochondrial K(ATP) channel play an important role in preconditioning of the heart following ischemia/reperfusion (I/R) injury. We investigated the cardioprotective effect of vardenafil (VAR) (Levitra), a highly selective and biochemically potent inhibitor of phosphodiesterase-5 (PDE-5) that enhances erectile function in men through up-regulation of cGMP. Rabbits were treated with VAR (0.014 mg/kg, iv) or volume-matched saline, 30 min prior to 30 min of sustained regional ischemia followed by 3 h of reperfusion. 5-hydroxydecanoate (5-HD, 5 mg/kg, iv) or HMR 1098 (HMR, 3 mg/kg, iv), the respective blockers of mitochondrial or sarcolemmal K(ATP) channels were administered 10 min before I/R. Infarct size was measured by computer morphometry of tetrazolium stained sections. Vardenafil treatment caused decrease in mean arterial blood pressure from 93.5+/-2.6 to 82.2+/-1.5 mmHg and increase in heart rate from baseline value of 151+/-20 to 196+/-4.6 bpm (mean+/-standard error of mean (S.E.M.), P<0.05) within 5 min. The infarct size (% of risk area) was reduced from 33.8+/-1.3 in control rabbits to 14.3+/-2.2 (58% reduction, P<0.05). 5-HD abolished VAR-induced protection as demonstrated by increase in infarct size to 34.5+/-2.3 (P<0.05, N=6 per group). In contrast, HMR failed to block the protective effect of VAR (infarct size, 14.3+/-2.2 versus 16.3+/-1.0 in VAR + HMR, P>0.05). Neither inhibitors of the K(ATP) channel influenced the infarct size in the control rabbits, as shown by infarct size of 34.9+/-1.1 and 33.3+/-1.4 in animals treated with 5-HD and HMR, respectively. For the first time, we demonstrate that VAR induces protective effect against I/R injury via opening of mitochondrial K(ATP) channel. These results further support our hypothesis that the novel class of PDE-5 inhibitors induce protective effect in the ischemic heart, in addition to their well known clinical effects in the treatment of erectile dysfunction in men.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16480739     DOI: 10.1016/j.yjmcc.2005.10.002

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  31 in total

1.  Beetroot juice reduces infarct size and improves cardiac function following ischemia-reperfusion injury: Possible involvement of endogenous H2S.

Authors:  Fadi N Salloum; Gregory R Sturz; Chang Yin; Shabina Rehman; Nicholas N Hoke; Rakesh C Kukreja; Lei Xi
Journal:  Exp Biol Med (Maywood)       Date:  2014-10-30

2.  HMR 1098 is not an SUR isotype specific inhibitor of heterologous or sarcolemmal K ATP channels.

Authors:  Hai Xia Zhang; Alejandro Akrouh; Harley T Kurata; Maria Sara Remedi; Jennifer S Lawton; Colin G Nichols
Journal:  J Mol Cell Cardiol       Date:  2010-12-23       Impact factor: 5.000

3.  PDE5 inhibitors enhance the lethality of standard of care chemotherapy in pediatric CNS tumor cells.

Authors:  Jane L Roberts; Laurence Booth; Adam Conley; Nichola Cruickshanks; Mark Malkin; Rakesh C Kukreja; Steven Grant; Andrew Poklepovic; Paul Dent
Journal:  Cancer Biol Ther       Date:  2014-03-20       Impact factor: 4.742

4.  Phosphodiesterase-5 inhibitor, tadalafil, protects against myocardial ischemia/reperfusion through protein-kinase g-dependent generation of hydrogen sulfide.

Authors:  Fadi N Salloum; Vinh Q Chau; Nicholas N Hoke; Antonio Abbate; Amit Varma; Ramzi A Ockaili; Stefano Toldo; Rakesh C Kukreja
Journal:  Circulation       Date:  2009-09-15       Impact factor: 29.690

5.  Cinaciguat, a novel activator of soluble guanylate cyclase, protects against ischemia/reperfusion injury: role of hydrogen sulfide.

Authors:  Fadi N Salloum; Anindita Das; Arun Samidurai; Nicholas N Hoke; Vinh Q Chau; Ramzi A Ockaili; Johannes-Peter Stasch; Rakesh C Kukreja
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-01-20       Impact factor: 4.733

Review 6.  Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection.

Authors:  Rakesh C Kukreja; Fadi N Salloum; Anindita Das
Journal:  J Am Coll Cardiol       Date:  2012-05-29       Impact factor: 24.094

7.  Phosphodiesterase 5 inhibitors enhance chemotherapy killing in gastrointestinal/genitourinary cancer cells.

Authors:  Laurence Booth; Jane L Roberts; Nichola Cruickshanks; Adam Conley; David E Durrant; Anindita Das; Paul B Fisher; Rakesh C Kukreja; Steven Grant; Andrew Poklepovic; Paul Dent
Journal:  Mol Pharmacol       Date:  2013-12-18       Impact factor: 4.436

8.  Cardiovascular protection with sildenafil following chronic inhibition of nitric oxide synthase.

Authors:  R C Kukreja
Journal:  Br J Pharmacol       Date:  2007-01-22       Impact factor: 8.739

9.  The phosphodiesterase-5 inhibitor vardenafil improves cardiovascular dysfunction in experimental diabetes mellitus.

Authors:  T Radovits; T Bömicke; G Kökény; R Arif; S Loganathan; K Kécsán; S Korkmaz; E Barnucz; P Sandner; M Karck; G Szabó
Journal:  Br J Pharmacol       Date:  2009-03-04       Impact factor: 8.739

10.  The effects of sildenafil citrate on ischemic colonic anastomotic healing in rats: its relationship between nitric oxide and oxidative stress.

Authors:  Hafize Uzun; D Konukoglu; M K Nuri; E Y Ersoy; S Ozçevik; N Yavuz
Journal:  World J Surg       Date:  2008-09       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.